<DOC>
	<DOCNO>NCT00003109</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase I trial study effectiveness irinotecan plus raltitrexed treating patient refractory solid tumor respond previous therapy .</brief_summary>
	<brief_title>Irinotecan Plus Raltitrexed Treating Patients With Refractory Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose irinotecan combination raltitrexed patient refractory solid tumor . II . Describe quantify toxic effect combination treatment regimen minimally pretreated patient population . III . Determine pharmacokinetics combination treatment regimen . IV . Document antitumor activity combination treatment regimen patient population . OUTLINE : This dose escalation study irinotecan raltitrexed . Patients receive irinotecan IV 90 minute day 1 8 follow raltitrexed IV 15 minute day 1 . Treatment repeat every 21 day absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos irinotecan raltitrexed maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose limit toxicity . Additional cohort receive raltitrexed day 2 rather day 1 near final dose level combination drug . PROJECTED ACCRUAL : A maximum 36 patient accrue study within 1 year .</detailed_description>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Raltitrexed</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically prove malignant solid tumor fail prior conventional chemotherapy establish therapy exist Recurrent metastatic gastrointestinal adenocarcinoma prior therapy eligible No evidence CNS metastasis ( brain leptomeningeal disease ) PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 01 Life expectancy : At least 12 week Hematopoietic : WBC least 3,500/mm3 Neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 1.8 mg/dL SGOT SGPT less 3 time upper limit normal ( ULN ) Alkaline phosphatase less 3 time ULN ( 5 time ULN metastatic disease ) Renal : Creatinine great 1.8 mg/dL OR Creatinine clearance least 60 mL/min Cardiovascular : No congestive heart failure Other : No uncontrolled diabetes Not pregnant nursing Negative pregnancy test No serious medical illness ( e.g . clinically active infectious process ) No psychiatric illness preclude study No ascites pleural effusion PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : At least 4 week since prior chemotherapy recover No 1 prior adjuvant chemotherapy regimen No 1 prior chemotherapy regimen recurrent metastatic disease No prior irinotecan raltitrexed At least 8 week since prior nitrosourea mitomycin recover Endocrine therapy : Not specify Radiotherapy : At least 4 week since prior radiotherapy recover Prior radiotherapy limit great 25 % bone marrow Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>